Vanguard Group Inc. Sells 156,306 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)

Vanguard Group Inc. cut its stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 1.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,154,376 shares of the biotechnology company’s stock after selling 156,306 shares during the quarter. Vanguard Group Inc. owned approximately 9.62% of Coherus BioSciences worth $15,393,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of CHRS. Steph & Co. bought a new stake in shares of Coherus BioSciences in the fourth quarter worth about $34,000. Intech Investment Management LLC bought a new position in shares of Coherus BioSciences during the fourth quarter valued at approximately $38,000. Ieq Capital LLC purchased a new position in Coherus BioSciences in the fourth quarter valued at about $68,000. Savant Capital LLC bought a new position in shares of Coherus BioSciences during the 4th quarter worth approximately $130,000. Finally, FMR LLC boosted its position in shares of Coherus BioSciences by 21.1% in the 3rd quarter. FMR LLC now owns 225,113 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 39,204 shares in the last quarter. Hedge funds and other institutional investors own 72.82% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on CHRS. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Coherus BioSciences in a research report on Tuesday, March 11th. StockNews.com lowered Coherus BioSciences from a “hold” rating to a “sell” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $5.38.

Coherus BioSciences Stock Performance

Shares of CHRS stock opened at $1.12 on Friday. Coherus BioSciences, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $2.43. The firm has a market capitalization of $129.80 million, a P/E ratio of -14.00 and a beta of 1.01. The stock’s fifty day moving average is $0.98 and its two-hundred day moving average is $1.12.

Coherus BioSciences Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.